Sorafenib inhibits LPS-induced inflammation by regulating Lyn-MAPK-NF-kB/AP-1 pathway and TLR4 expression

Anti-Inflammatory Effect of Sulforaphane on LPS-Activated Microglia Potentially through JNK/AP-1/NF-κB Inhibition and Nrf2/HO-1 Activation

(2019) Lalita Subedi et al.   Cells

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib

(2019) Oronzo Brunetti et al.   Medicina-Lithuania

Src family kinase tyrosine phosphorylates Toll-like receptor 4 to dissociate MyD88 and Mal/Tirap, suppressing LPS-induced inflammatory responses

(2018) Jonathon Mitchell et al.   BIOCHEMICAL PHARMACOLOGY

Sorafenib inhibits caspase-1 expression through suppressing TLR4/stat3/SUMO1 pathway in hepatocellular carcinoma

(2018) Jun Li et al.   CANCER BIOLOGY & THERAPY

Sorafenib for the treatment of breast cancer

(2017) Giuseppe Bronte et al.   EXPERT OPINION ON PHARMACOTHERAPY

Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014

(2017) Chanu Rhee et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Association of Lyn kinase with membrane rafts determines its negative influence on LPS-induced signaling

(2017) Kinga Borzęcka-Solarz et al.   MOLECULAR BIOLOGY OF THE CELL

Early, Goal-Directed Therapy for Septic Shock — A Patient-Level Meta-Analysis

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury

(2017) Sofie Martens et al.   Cell Death & Disease

Lyn regulates mucus secretion and MUC5AC via the STAT6 signaling pathway during allergic airway inflammation

(2017) Xiaoyun Wang et al.   Scientific Reports

Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations

(2016) Carolin Fleischmann et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Sorafenib for the treatment of multiple myeloma

(2016) Massimo Gentile et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Potential therapeutic targets for inflammation in toll-like receptor 4 (TLR4)-mediated signaling pathways

(2016) Anjali Roy et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

(2016) Mervyn Singer et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Selective use of sorafenib in the treatment of thyroid cancer

(2016) Fabián Pitoia et al.   Drug Design Development and Therapy

The Tyrosine Kinase c-Src Specifically Binds to the Active Integrin αIIbβ3 to Initiate Outside-in Signaling in Platelets

(2015) Yibing Wu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bactericidal antibiotics promote reactive oxygen species formation and inflammation in human sinonasal epithelial cells

(2015) Michael A. Kohanski et al.   International Forum of Allergy & Rhinology

Src family kinases: at the forefront of platelet activation

(2014) Y. A. Senis et al.   BLOOD

Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit

(2014) Jean-Louis Vincent et al.   Lancet Respiratory Medicine

Lyn Mitigates Mouse Airway Remodeling by Downregulating the TGF- 3 Isoform in House Dust Mite Models

(2013) G. Li et al.   JOURNAL OF IMMUNOLOGY

Lyn kinase controls TLR4-dependent IKK and MAPK activation modulating the activity of TRAF-6/TAK-1 protein complex in mast cells

(2012) Martin Avila et al.   Innate Immunity

Dissecting negative regulation of Toll-like receptor signaling

(2012) Takeshi Kondo et al.   TRENDS IN IMMUNOLOGY

Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity

(2011) Taro Kawai et al.   IMMUNITY

Hck Tyrosine Kinase Regulates TLR4-Induced TNF and IL-6 Production via AP-1

(2011) M. J. Smolinska et al.   JOURNAL OF IMMUNOLOGY

NLRC5 Negatively Regulates the NF-κB and Type I Interferon Signaling Pathways

(2010) Jun Cui et al.   CELL

The multikinase inhibitor Sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE2 in murine macrophages

(2010) Justin P. Edwards et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

The TAK1–TRAF6 signalling pathway

(2010) Marene Landström   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

(2008) M. M. Hipp et al.   BLOOD

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS